Mike Margarson
Impact in
- Infectious Diseases top 0.5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 7
-
- Clinical Nutrition and Gastroenterology 1
Mike Margarson
9 papers receiving 3k citations
Mike Margarson's Hit Papers
Peers
Comparison fields: 5 of 96
- Infectious Diseases 2.4k
- Applied Microbiology and Biotechnology 40
- Internal Medicine 30
- Oncology 145
- Statistics and Probability 76
Countries citing papers authored by Mike Margarson
This map shows the geographic impact of Mike Margarson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mike Margarson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mike Margarson more than expected).
Fields of papers citing papers by Mike Margarson
This network shows the impact of papers produced by Mike Margarson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mike Margarson. The network helps show where Mike Margarson may publish in the future.
Co-authors
The 6 scholars most cited alongside Mike Margarson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 1531 |
| 2 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 3 | Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial Hit paper breakdown → | 2021 | 393 |
| 4 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 5 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 6 | 2021 | 213 | |
| 7 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 8 | 2025 | 13 | |
| 9 | 2017 | 9 |
About Mike Margarson
Mike Margarson is a scholar working on Infectious Diseases, Nutrition and Dietetics, Physiology, Pulmonary and Respiratory Medicine and Epidemiology, having authored 9 papers that have together received 3.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (7 papers), Body Composition Measurement Techniques (1 paper), Clinical Nutrition and Gastroenterology (1 paper), Sepsis Diagnosis and Treatment (1 paper) and Respiratory Support and Mechanisms (1 paper). The work is most often cited by research in Infectious Diseases (2.4k citations), Applied Microbiology and Biotechnology (40 citations), Internal Medicine (30 citations), Oncology (145 citations) and Statistics and Probability (76 citations). Mike Margarson has collaborated with scholars based in United Kingdom, Denmark and Vietnam. Frequent co-authors include Jerome Wulff, David A Harrison, Anne Pernille Toft‐Petersen, Kathy Rowan, Marlies Ostermann and Deborah Dawson. Their work appears in journals such as The Lancet, JAMA and Journal of Critical Care.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.